Abstract: Cervical cancer is one of the common malignant tumors in women，which seriously threatens women's life and health. At present，neoadjuvant chemotherapy（NACT）is an important adjuvant treatment for cervical cancer before surgery or radiotherapy in China. However，due to the tumor heterogeneity of cervical cancer and individual differences in patients' sensitivity to chemotherapy，not all patients can benefit from NACT treatment. A simple and effective means to predict patients' chemotherapy sensitivity to NACT in a timely manner would help clinicians to adjust treatment plans in a timely manner and prevent patients who are not sensitive to NACT from missing the best opportunities for surgery or radiotherapy. This article presents the research progress on the prediction of NACT sensitivity in cervical cancer in terms of histopathology，biomarkers of patients and models of cancerous organs from patients，which will help to identify whether patients will benefit from NACT，stratify patients with different sensitivities，and promote the precise treatment of cervical cancer.

Key words: cervical cancer, neoadjuvant chemotherapy, sensitivity, prediction

摘要： 子宫颈癌是常见的女性恶性肿瘤之一，严重威胁女性生命健康。目前，新辅助化疗（neoadjuvant chemotherapy，NACT）是我国子宫颈癌手术前或放疗前辅助治疗的重要手段。然而，由于子宫颈癌的肿瘤异质性和患者对化疗敏感性的个体差异等因素的存在，并非所有患者都能从NACT治疗中获益。若能借助简单易行的手段及时且有效预测患者对 NACT 的化疗敏感性，将有助于临床医生及时调整治疗方案，避免对 NACT 不敏感患者错失最佳手术或放疗机会。文章从子宫颈癌组织病理学、患者的生物标志物以及患者来源的癌症类器官模型等方面介绍其对子宫颈癌NACT敏感性预测的研究进展，有利于甄别患者是否会从NACT中获益，对不同敏感性患者进行精准分层，促进子宫颈癌的精准治疗。

关键词: 子宫颈癌, 新辅助化疗, 敏感性, 预测